Actively Recruiting
Phase IbII Study of Regorafenib with Toripalimab and Albumin-bound Paclitaxel as Third-Line Treatment for Advanced Pancreatic Cancer
Led by Junjie Hang · Updated on 2026-05-18
23
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of combining Regorafenib with Toripalimab and Albumin-bound Paclitaxel as a third-line treatment for patients with unresectable or metastatic pancreatic cancer. This trial aims to determine the best dose of Regorafenib and assess how well this combination works and its safety in this patient group. The study has two phases Phase Ib focuses on finding the maximum tolerated dose of Regorafenib with fixed doses of Toripalimab and Paclitaxel-albumin, given in cycles every three weeks. Phase II uses the recommended dose from Phase Ib to further evaluate efficacy and safety. Treatments are given until the cancer progresses or side effects become intolerable. Participants will undergo regular assessments including tumor imaging to measure progression-free survival, objective response rate, and overall survival up to 60 months. Safety and tolerability will be closely monitored. The total participation duration depends on treatment response and tolerability. The trial includes adults aged 18 to 80 with confirmed advanced pancreatic cancer who have progressed after standard treatments.
CONDITIONS
Brief Title
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Research Team
H
Hang Junjie, doctorate
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
